Glaxo And IRS To Square Up In International Tax Dispute

British pharmaceutical firm GlaxoSmithKline (GSK) isObama intends to restrict the use of this financing
gearing up for a multi-billion dollar tax fight with the UStechnique in his international tax reforms, presented as
Internal Revenue Service in a keenly-watched casepart of the 2010 budget blueprint.
which could affect how multinationals structure theirThe tax dispute with the US authorities is
international affairs.acknowledged in GSK’s 2008 annual report, which
The case centres on a practice known asstated that Statutory Notices of Deficiency were
‘earnings stripping,’ whereby allegedlyissued by the IRS following its audit of the period 2001
‘excessive’ payments of deductible interest areto 2003. These Notices “assert income and
made by foreign-controlled US corporations to relatedwithholding tax deficiencies, and associated penalties,
persons in whose hands that interest is partially or fullyarising from its reclassification of an inter-company
exempt from US tax. For example, the company mayfinancing arrangement in those years from debt to
create a debt obligation from the corporation’s newequity, and its consequent recharacterization of the
US subsidiary to the new foreign parent, typicallyamounts paid as dividends subject to withholding tax
incorporated in a low-tax jurisdiction. The interestunder the US – UK treaty.”
payments on this related-party debt create deductionsWhile the report said that all amounts due under the
that reduce US tax without creating an offsettingfinancing arrangement “were timely paid,” the
increase in the foreign tax due.IRS is now taking issue with aspects of GSK’s tax
Earnings stripping was one of three international taxarrangements for the period 2004 to 2006. “GSK
issues examined in a US Treasury Department reportdisagrees with the IRS’s position,” the report
sent to Congress in November 2008, the other twostated, adding that the company has initiated actions in
being transfer pricing and US tax treaties. This studythe United States Tax Court to contest the Notices.
concluded that it is “not possible” to quantifyGSK estimates that the IRS claim for tax, penalties,
accurately the extent of earnings stripping generally,and interest at December 31, 2008, net of federal tax
although it said that “strong evidence exists” ofrelief, for 2001 through 2003 is USD864m. If the IRS
earnings stripping by foreign-controlled domesticprevails in its argument before a court in respect of
corporations that have undergone so-called "inversion"the years 2001-2003, GSK expects to have an
transactions, in which the US parent company of aadditional liability for the five year period 2004-2008 of
multinational corporate group is replaced with a foreignUSD1.06bn in tax, penalties, and interest.
parent in a low-tax or no-tax country. President